Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

689results about How to "Long duration of action" patented technology

Prodrugs of nh-acidic compounds

ActiveUS20110003828A1Reduce polarity and solubilityLong duration of actionBiocideNervous disorderDrugUrea
The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
Owner:ALKERMES PHARMA IRELAND LTD

Methods and compositions for the treatment of neuropsychiatric disorders

InactiveUS20060089350A1Improve lipophilicityReduced diuretic effectBiocideNervous disorderDiseaseNeuropathic pain
The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and / or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1.
Owner:NEUROPRO THERAPEUTICS

Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions

Disclosed herein are novel buprenorphine monocarboxylic ester derivatives and dibuprenorphine dicarboxylic ester derivatives which exert a longer analgesic effect as compared to buprenorphine hydrochloride. Also disclosed are the processes for synthesizing the novel ester derivatives of buprenorphine, and long-acting analgesic pharmaceutical compositions containing a compound selected from buprenorphine base and the novel ester derivatives of buprenorphine.
Owner:CHI MEI MEDICAL CENT

Oral transmucosal methadone

InactiveUS20050065175A1Safer and effective analgesic reliefLong duration of actionBiocidePowder deliveryDrugOral mucosa
Pharmaceutical compositions for oral-transmucosally administering methadone. For oral transmucosal delivery, the compositions comprise an oral dissolution agent and methadone in a dosage formulation. The dissolution agent generally causes the formulation to break down or dissolve in the oral cavity. The formulation is buffered to a pH of at least 6 for substantial absorption of the methadone through the oral mucosal tissue from the dissolved dosage form.
Owner:GONZALES GILBERT R +1

Melanocortin receptor-specific peptides

InactiveUS20100311648A1Reducing food intakeReducing body weight body gainNervous disorderMetabolism disorderOverweightDisease
The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I)or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and / or energy balance and body weight related diseases, disorders and / or conditions, including obesity, overweight and diseases, disorders and / or conditions associated with obesity and / or overweight, such as type 2 diabetes and metabolic syndrome.
Owner:ASTRAZENECA AB

Imaging system and imaging method

To effectively and reliably acquire detailed images of plural moving subjects in the case where a fixed camera or a pan/tilt camera for searching the moving subject and another pan/tilt camera for taking an image of the details of the moving subject by zooming the moving subjects are used to detect the moving subjects. An imaging system including a sensor camera, a zoom camera, and a controller that controls the sensor camera and zoom camera, and includes a moving subject detection unit extracting the position and the size of a moving subject from a sensor image, an imaging angle of view calculation unit determining one imaging angle of view based on plural moving subjects extracted by the moving subject detection unit, a unit allowing the zoom camera to perform imaging of the area specified depending on the position of the angle, moving speed, and size determined by the imaging angle of view calculation unit, a unit managing the order of the imaging operation of the zoom camera, a unit holding the imaging angle of view for a given time at the time when all the moving subjects in the imaging angle of view become static, and a unit calculating the imaging position in the imaging area of the sensor camera, and assigns ID to an imaging angle of view, assigns the same angle of view ID to the imaging angle even after the moving subject becomes static, controls the priority of the imaging operation of the imaging angle of view including the same moving subject, and allows the zoom camera to take an image of a tracking target in the imaging area of the sensor camera while performing wide-angle imaging with the sensor camera.
Owner:SONY CORP

Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors

The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like.A proton pump inhibitor containing a compound represented by the formula (I)wherein ring A is a saturated or unsaturated 5- or 6-membered ring group optionally having, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, ring-constituting atoms X1 and X2 are each a carbon atom or a nitrogen atom, a ring-constituting atom X3 is a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, R1 is an optionally substituted aryl group or an optionally substituted heteroaryl group, R2 is an optionally substituted alkyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group, R3 is an aminomethyl group optionally substituted by 1 or 2 lower alkyl groups, which is a substituent on a ring-constituting atom other than X1, X2 and X3, and ring A optionally further has substituent(s) selected from a lower alkyl group, a halogen atom, a cyano group and an oxo group, or a salt thereof or a prodrug thereof.
Owner:TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products